These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16022110)

  • 1. [Pharmacogenomical aspects of gastroesophageal reflux disease].
    Isaev VA
    Vestn Ross Akad Med Nauk; 2005; (6):33-6. PubMed ID: 16022110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C19 genotype and the PPIs--focus on rabeprazole.
    Lim PW; Goh KL; Wong BC
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
    Park SH
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
    [No Abstract]   [Full Text] [Related]  

  • 5. [Dosaging of proton pumps inhibitors].
    Brørs O
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2397-9. PubMed ID: 16998554
    [No Abstract]   [Full Text] [Related]  

  • 6. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
    Furuta T; Sugimoto M; Shirai N; Ishizaki T
    Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent anaphylaxis linked to pantoprazole.
    Kollmeier AP; Eddleston J; Zuraw BL; Christiansen SC
    J Allergy Clin Immunol; 2004 Oct; 114(4):975-7. PubMed ID: 15480345
    [No Abstract]   [Full Text] [Related]  

  • 8. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
    Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
    Shirai N; Furuta T
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():439-44. PubMed ID: 11979823
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
    Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
    Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.
    Wada F; Murase K; Isomoto H; Soda H; Takeshima F; Omagari K; Mizuta Y; Tsukamoto K; Murata I; Kohno S
    J Int Med Res; 2002; 30(4):413-21. PubMed ID: 12235924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
    Lim PW; Goh KL
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
    Shirai N; Furuta T; Sugimoto M; Nakamura A
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():438-41. PubMed ID: 16363575
    [No Abstract]   [Full Text] [Related]  

  • 17. [PPI: new strategies for GERD].
    Hoshino E; Ishiyama A; Tsuchida T
    Nihon Rinsho; 2004 Aug; 62(8):1570-6. PubMed ID: 15344553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic studies on PPIs: look carefully at the country of origin.
    Savarino V; Savarino E; Dulbecco P
    Dig Liver Dis; 2006 Nov; 38(11):808-10. PubMed ID: 16945598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.